Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasinezumab (PRX002) Multiple Ascending Dose in Parkinson's Disease
NCT02157714Phase 1Completed
- Sponsor
- Prothena Corporation
- Start
- Jun 2014
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing PRX002 with Placebo (2 arms). Primary endpoints: Safety and tolerability as determined by number of subjects with adverse events up to 6 months and Determination of pharmacokinetics parameters up to 6 months. Started Jun 2014; status: completed.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02157714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157714.